The purpose of this research study is to determine if the EGFR mutation can be detected in CTCs. CTCs are cancer cells that are shed from solid tumors and float freely in the bloodstream. A device called the CTC-chip has been developed to find CTCs in the blood of patients with cancer. This is an experimental device. Using this device, the investigators will test participants' blood to try and find CTCs with the EGFR mutation and compare them with the results from the biopsy your doctor has recommended. The long-term goal of this research is to develop a way to test for the EGFR mutation that is less invasive than a tumor biopsy.
Name: Circulating tumor cell chip
Description: Calculate the number of patients in the study population with detectable EGFR mutations in the CTCs in order to demonstrate the feasibility of testing for EGFR mutations from captured CTCsMeasure: Number of patients with detectable EGFR mutations in their CTCs Time: 2 years
Description: Determine the concordance of EGFR genotyping from CTCs compared to tumor tissueMeasure: Number of patients with CTC-derived EGFR genotyping matching their tumor-derived EGFR genotyping Time: 2 yearss
Description: Explore the feasibility of EGFR genotyping from plasma circulating free DNA (cfDNA)Measure: Number of patients with EGFR gentoype results detectable from plasma cfDNA Time: 2 years
There is one SNP
Detecting EGFR T790M Mutations From Circulating Tumor Cells. --- T790M ---
Detecting EGFR T790M Mutations From Circulating Tumor Cells The purpose of this research study is to determine if the EGFR mutation can be detected in CTCs. --- T790M ---